CYCLOPENTA [D] PYRIMIDINE AS AKT PROTEIN KINASE INHIBITOR

• Main Authors: SCHLACHTER STEPHEN T, XIAO DENGMING, SAFINA BRIAN, BENCSIK JOSEF R, LIANG JUN, BANKA ANNA L, BLAKE JAMES F, MITCHELL IAN S, XU RUI, LI CHUN, CHABOT CHRISTINE, SPENCER KEITH LEE, KALLAN NICHOLAS C, WALLACE ELI W
• Format: Patent
• Language: English
• Published: 14.11.2013
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; COMPOSITIONS THEREOF; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; CULTURE MEDIA; ENZYMOLOGY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

PROBLEM TO BE SOLVED: To provide novel compounds as AKT protein kinase inhibitors.SOLUTION: The present invention provides cyclo [D] pyrimidine derivative compound having general formula (I), enantiomers, and salts thereof. Also provided are methods of using the compounds as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer. In the formula, A is a nitrogen-substituted aralkylacyl residue or the like; and R, R, R, R, and Rare a hydrogen atom or the like.